Skip to content
Indapamide
Lozol (indapamide) is a small molecule pharmaceutical. Indapamide was first approved as Lozol on 1983-07-06. It is used to treat edema, heart failure, hypertension, and nephrotic syndrome in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
urogenital diseasesD000091642
cardiovascular diseasesD002318
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Indapamide
Tradename
Company
Number
Date
Products
LOZOLSanofiN-018538 DISCN1983-07-06
2 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
indapamideANDA2021-03-31
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
edema—D004487R60.9
heart failureEFO_0003144D006333I50
hypertensionEFO_0000537D006973I10
nephrotic syndromeEFO_0004255D009404N04
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C03: Diuretics
— C03B: Low-ceiling diuretics, excl. thiazides
— C03BA: Sulfonamides, low-ceiling diuretics, plain
— C03BA11: Indapamide
— C09: Agents acting on the renin-angiotensin system
— C09B: Ace inhibitors, combinations
— C09BX: Ace inhibitors, other combinations in atc
— C09BX01: Perindopril, amlodipine and indapamide
— C10: Lipid modifying agents
— C10B: Lipid modifying agents, combinations
— C10BX: Lipid modifying agents in combination with other drugs
— C10BX13: Rosuvastatin, perindopril and indapamide
HCPCS
No data
Clinical
Clinical Trials
2 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
LeukemiaD007938C95—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Breast neoplasmsD001943EFO_0003869C501————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameINDAPAMIDE
INNindapamide
Description
Indapamide is a sulfonamide formed by condensation of the carboxylic group of 4-chloro-3-sulfamoylbenzoic acid with the amino group of 2-methyl-2,3-dihydro-1H-indol-1-amine. It has a role as an antihypertensive agent and a diuretic. It is a member of indoles, an organochlorine compound and a sulfonamide. It is functionally related to a benzamide.
Classification
Small molecule
Drug classdiuretics (sulfamoylbenzoic acid derivatives)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC1Cc2ccccc2N1NC(=O)c1ccc(Cl)c(S(N)(=O)=O)c1
Identifiers
PDB—
CAS-ID26807-65-8
RxCUI5764
ChEMBL IDCHEMBL406
ChEBI ID5893
PubChem CID3702
DrugBankDB00808
UNII IDF089I0511L (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 2,952 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
5 adverse events reported
View more details